Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.49 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.49 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.49 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.43 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3773188 | 0.89 | CTDSP1 (0.48) | CTDSP1ATMMAPTAPOBEC3ADUSP3 | |
| SCHEMBL3766952 | 0.89 | ATM (0.43) | CTDSP1ATMMAPTAPOBEC3ADUSP3 | |
| SCHEMBL3634346 | 0.88 | CTDSP1 (0.55) | CTDSP1ATMMAPTAPOBEC3ADUSP3 | |
| SCHEMBL3766960 | 0.88 | CTDSP1 (0.53) | CTDSP1ATMMAPTAPOBEC3ADUSP3 | |
| SCHEMBL3763396 | 0.87 | CTDSP1 (0.52) | CTDSP1ATMMAPTAPOBEC3ADUSP3 | |
| SCHEMBL3768510 | 0.87 | CTDSP1 (0.54) | CTDSP1ATMMAPTAPOBEC3ADUSP3 | |
| SCHEMBL3634049 | 0.87 | CTDSP1 (0.52) | CTDSP1ATMMAPTAPOBEC3ADUSP3 | |
| SCHEMBL3773365 | 0.87 | CTDSP1 (0.62) | CTDSP1ATMMAPTAPOBEC3ADUSP3 | |
| SCHEMBL3767136 | 0.86 | CTDSP1 (0.46) | CTDSP1ATMMAPTAPOBEC3ADUSP3 | |
| SCHEMBL3769135 | 0.85 | CTDSP1 (0.50) | CTDSP1ATMMAPTAPOBEC3ADUSP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311741-A1 | Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents | INHIBOX LTD. (GB) | 2010-12-09 | — | — | US | disclosed |
| US-20100311741-A1 | Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents | INHIBOX LTD. (GB) | 2010-12-09 | — | — | US | disclosed |
| US-20100311741-A1 | Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents | INHIBOX LTD. (GB) | 2010-12-09 | — | — | US | disclosed |
| WO-2008142376-A1 | BICYCLOSULFONYL ACID (BCSA) COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | INHIBOX LTD. (GB) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311741-A1 | Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents | TNF, CS, COASY | CTDSP1 725/4885ATM 765/4885MAPT 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.